News | July 05, 2007

Toshiba to Offer New PV-CTA Training Course

July, 6, 2007 – Toshiba America Medical Systems, Inc. announced a partnership with CVCTA Education to provide a Peripheral Vascular CTA (PV-CTA) training course in a move to strengthen its position in medical education and improved patient care.
This course will be the first of its kind to exceed current ACCF/AHA Level 2 requirements in the ACCF/AHA Clinical Competence Statement on Cardiac Imaging with Computed Tomography and Magnetic Resonance.
“PV-CTA is one of the most accurate and important non-invasive diagnostic tools available to detect PVD in patients reporting symptoms and in those who are asymptomatic,” said Doug Ryan, senior director, CT Business Unit. “Partnering with CVCTA Education to offer a comprehensive PV-CTA educational course is a step toward ensuring that PVD is properly detected and treated.”
The PV-CTA training course will be offered at CVCTA Training Centers in San Francisco, New York and Houston, several times per month with the first course starting in September. The course will use a blend of online learning and in-person training on Toshiba’s leading Aquilion CT scanners. Students will complete six hours of online didactics covering a review of anatomy and function, as well as findings and reporting. Also, in one day of hands-on workstation training, the students will be mentored on more than 25 cases of varying pathology. Students also will work on more than 75 cases via CVCTA’s proprietary MedMind CTA training software.
Created by Dr. Peter Fail from the Cardiovascular Institute of the South and Dr. Tony DeFrance from CVCTA, the PV-CTA course will provide students with more than 100 mentored cases with a wide variety of pathology, therefore exceeding the anticipated Level 2 requirements set by the ACCF and AHA. In total, the student will receive 40 hours of CME credit.
“PV-CTA will play an important role in helping imaging centers and hospitals educate the community on the emerging information and issues regarding the overall impact of PVD and the value of this diagnostic tool,” said Tony DeFrance, M.D., medical director of CVCTA Education.

For more information: www.medical.toshiba.com and www.cvcta.com

Related Content

Lokai Medical to Distribute NuCryo Vascular PolarCath Balloon Dilatation System in U.S.
News | Peripheral Artery Disease (PAD) | August 14, 2018
NuCryo Vascular announced that the company has signed a commercialization agreement with Lokai Medical, a specialty...
PQ Bypass Effective in Treating Extremely Long SFA Lesions at 12 Months
News | Peripheral Artery Disease (PAD) | July 02, 2018
The PQ Bypass Detour System showed promising 12-month durability for patients with extremely long blockages in the...
SCAI Releases Consensus Guidelines for Femoral-Popliteal Arterial Interventional Device Selection
News | Peripheral Artery Disease (PAD) | May 15, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) has released new guidelines to address the...
SCAI Launches Diagnosis and Treatment Toolkit for Peripheral Artery Disease
News | Peripheral Artery Disease (PAD) | May 14, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) announced the launch of the SCAI PAD Diagnosis and...
Critical Limb Ischemia Treatment Shows No Improvement at Three Months
News | Peripheral Artery Disease (PAD) | March 23, 2018
Patients with foot ulcers or gangrene who received the experimental drug JVS-100 did not show evidence of faster wound...
FDA Clears Corindus CorPath GRX for Peripheral Vascular Interventions
Technology | Peripheral Artery Disease (PAD) | February 20, 2018
Corindus Vascular Robotics Inc. announced today that it received 510(k) clearance from the U.S. Food and Drug...
News | Peripheral Artery Disease (PAD) | December 29, 2017
December 29, 2017 — iVascular announced the release of the new Oceanus 14 Pro percutaneous transluminal angioplasty (
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD) | September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD) | September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD) | September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init